Compare TransMedics Group Inc (TMDX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs US Bancorp — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while US Bancorp trades at $57.08 (market cap $88.86B). The key difference: US Bancorp is far larger — about 32.4× TransMedics Group Inc's market cap, and US Bancorp pays a 3.79% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and US Bancorp for 97 Days on average.
| TMDX | USB | |
|---|---|---|
Market Cap | $2.74B | $88.86B |
Volume | 949,331 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $150.42 | $65.42 |
52-Week Low | $61.99 | $45.28 |
Typical Hold Time | 24 Days | 97 Days |
Enterprise Value | $3.13B | $118.35B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
U.S. Bancorp (USB) trades at $57.08, up 1.62% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 11.38 and net income margin of 27.61%, supported by three consecutive quarterly earnings beats. Recent news highlights dividend increases and positive Q3 2026 revenue expectations, though technical indicators suggest near-term pressure with key support at $55.
USB presents a compelling value opportunity with analyst consensus price target of $69.94 (22.5% upside) and 51% buy ratings. Risks include regulatory changes and interest rate sensitivity, but strong profitability metrics and institutional confidence support long-term growth prospects in the regional banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
